Virtual Event | October 27, 2026

From Multiomics To Medicines: Turning Complex Biology Into Better Drug Candidates

Source: Drug Discovery Online

 

Scientists have never had more ways to interrogate biology. The harder question is whether all that data actually changes a decision. From Multiomics to Medicines: Turning Complex Biology into Better Drug Candidates, sponsored by Emulate, looked past the hype to ask what it takes to make multiomics useful inside real discovery organizations. It was moderated by Ray Dogum, Chief Editor of Drug Discovery Online, who guided the discussion and fielded a steady stream of audience questions throughout the event.

Key Takeaways:

Jurre Kamphorst, Ph.D., Director of Multiomics at AstraZeneca, described multiomics as a toolset, not an end in itself. Its greatest value comes when a project team hits an uncertainty that conventional methods can't resolve. That moment can arrive anywhere from target identification to late-stage safety work. Asked how often multiomics evidence had changed a program decision at AstraZeneca in the past year, he said "certainly five plus times." Higher than the average live audience poll response to this question. He also pointed to growing FDA acceptance, including guidance on platforms like Olink and SomaLogic. Kamphorst said his team routinely goes back to stakeholders to ask, "Hey, how did it actually change?" When sample sizes are out of their control, the team states the study's limits up front and treats the results as a starting point for a hypothesis they can test.

Organoids and other human-relevant models also came up. Kamphorst said his team does more and more work with advanced cell models because they bring "human biological relevance closer and earlier in our drug projects." The team often profiles these models with bulk RNA-seq, which is cheap and fast. An audience member asked which is better for confirming that tumor organoids match the tumor tissue they came from: whole genome sequencing or bulk RNA-seq. Kamphorst said the answer depends on the biology in question. He added that proteomics, cell surface proteomics, or lipidomics may be the better choice.

Ahmet F. Coskun, Ph.D., Bernie-Marcus Early-Career Professor and Associate Professor of Biomedical Engineering at Georgia Tech and Emory University, explained how each technique adds resolution. Bulk RNA-seq lists the parts, single-cell analysis shows which cells drive them, and spatial omics "really puts them all into context at the end." He explained that image-based spatial transcriptomics is usually more sensitive than sequencing-based methods because it skips cDNA conversion, a step that can cut capture efficiency from 50% or more to a few percent. He also named a key limit of mass spectrometry: "You can detect things, but you may not be able to name things." 

The panel also took on the field's growing pains. New analysis tools seem to appear weekly. Coskun advised judging them by citations, documentation, and how widely other labs have adopted them, noting that over time "the best algorithms will survive." He warned that AI-based gap-filling of missing patient data can produce targets that "may not be real." He pointed out that exposomics is still stuck in correlation rather than causation. Comparing today's tools with the earlier shift from qPCR and microarrays to the clinic, he estimated it will take "half a decade or a decade" to establish clinical standards. 

Live audience polls added a reality check:

  • Layers: Two omics layers was the most common setup (31%), and 23.5% of respondents don't routinely integrate omics data at all.
  • Decisions: 44.5% said they don't track whether multiomics has changed a program decision, and none reported more than five such decisions.
  • Stage: Target identification led as the stage where multiomics most often shapes decisions (45.5%).

Access The Virtual Event!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.

Subscribe to Drug Discovery Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Drug Discovery Online